Abstract:Idiopathic Pulmonary Fibrosis (IPF) is characterized by progressive fibrosis and chronic lung tissue remodeling with a 3-5-year median patient survival, post-diagnosis. Overproduction of extracellular matrix (ECM) by activated myofibroblasts as a result of cytokines like transforming growth factor β (TGFβ) is a key feature of IPF. Novel antifibrotics are urgently needed since the approved therapies only slow down disease progression. We took a top-down approach to drug discovery, conducting high-content drug screenings & structure-activity relationship (SAR) studies leading to the discovery of a new class of potent antifibrotics N-(2-butoxyphenyl)-3-phenyl)acrylamides (N23Ps). For lead development, we conducted a comprehensive SAR analysis on N23P-derivatives using high-content ECM deposition assays with primary IPF-derived lung fibroblasts. Here, collagen V & fibulin-1 deposition by these fibroblasts were measured against varying concentrations of N23Ps. Biological and technical replicates across 115 experiments with 142 compounds and varying degrees of structural alterations led to a complex set of dose-response data. To address the complexity and to automate the analysis, we developed metaSAR, a computational pipeline to estimate compound activities and characteristics from dose-response curves while considering outliers, edge effects, and plate & curve quality. Using cheminformatic tools and regression models, we could successfully identify chemical groups and locations associated with potency which ultimately led to highly potent & stable N23P derivates. To elucidate their effects on the lung microenvironment, we are now conducting single-cell RNA sequencing on perturbed human precision-cut lung slices.

The Discovery of MORF-627, a Highly Selective Conformationally-Biased Zwitterionic Integrin αvβ6 Inhibitor for Fibrosis

The Discovery of MORF-627, a Highly Selective Conformationally-Biased Zwitterionic Integrin αvβ6 Inhibitor for Fibrosis

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1

Discovery of a new class of integrin antibodies for fibrosis

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic αvβ6 Integrin Inhibitors

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors

Lead optimization and mode-of-action elucidation for novel antifibrotics

Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma

Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Core Modifications of GSK3335103 toward Orally Bioavailable α v β 6 Inhibitors with Improved Synthetic Tractability

Design, synthesis and biological evaluation studies of novel anti-fibrosis agents bearing sulfoxide moiety

Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket

Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis.